Aileron Therapeutics Inc (NASDAQ:ALRN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price target of $19.33 for the company and are forecasting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aileron Therapeutics an industry rank of 193 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th.
Aileron Therapeutics (NASDAQ:ALRN) opened at $8.94 on Tuesday. Aileron Therapeutics has a fifty-two week low of $7.38 and a fifty-two week high of $15.48.
In related news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total value of $1,470,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
A number of large investors have recently modified their holdings of ALRN. California State Teachers Retirement System bought a new stake in Aileron Therapeutics in the third quarter worth $110,000. Vanguard Group Inc. bought a new stake in Aileron Therapeutics in the second quarter worth $111,000. Bank of New York Mellon Corp bought a new stake in Aileron Therapeutics in the third quarter worth $135,000. Schwab Charles Investment Management Inc. bought a new stake in Aileron Therapeutics in the third quarter worth $165,000. Finally, Goldman Sachs Group Inc. bought a new stake in Aileron Therapeutics in the second quarter worth $418,000. Hedge funds and other institutional investors own 7.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks: Aileron Therapeutics Inc (ALRN) Given Consensus Rating of “Strong Buy” by Brokerages” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/21/zacks-aileron-therapeutics-inc-alrn-given-consensus-rating-of-strong-buy-by-brokerages.html.
About Aileron Therapeutics
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.